Skip to main content
Current Research in Pharmacology and Drug Discovery logoLink to Current Research in Pharmacology and Drug Discovery
. 2022 Nov 3;3:100137. doi: 10.1016/j.crphar.2022.100137

Recent developments on UDP-N-acetylmuramoyl-L-alanine-D-gutamate ligase (Mur D) enzyme for antimicrobial drug development: An emphasis on in-silico approaches

Vinita Gaur 1, Surojit Bera 1,
PMCID: PMC9780078  PMID: 36568273

Abstract

Introduction

The rapid emergence of antibiotic resistance among various bacterial pathogens has been one of the major concerns of health organizations across the world. In this context, for the development of novel inhibitors against antibiotic-resistant bacterial pathogens, UDP-N-Acetylmuramoyl-L-Alanine-D-Glutamate Ligase (MurD) enzyme represents one of the most apposite targets.

Body

The present review focuses on updated advancements on MurD-targeted inhibitors in recent years along with genetic regulation, structural and functional characteristics of the MurD enzyme from various bacterial pathogens. A concise account of various crystal structures of MurD enzyme, submitted into Protein Data Bank is also discussed.

Discussion

MurD, an ATP dependent cytoplasmic enzyme is an important target for drug discovery. The genetic organization of MurD enzyme is well elucidated and many crystal structures of MurD enzyme are submitted into Protein Data bank. Various inhibitors against MurD enzyme have been developed so far with an increase in the use of in-silico methods in the recent past. But cell permeability barriers and conformational changes of MurD enzyme during catalytic reaction need to be addressed for effective drug development. So, a combination of in-silico methods along with experimental work is proposed to counter the catalytic machinery of MurD enzyme.

Keywords: Antibiotic resistance, Peptidoglycan, MurD, In-silico

Abbreviations: PG, Peptidoglycan; UDP-GlcNAc, UDP-N-acetylglucosamine; UDP-MurNAc, UDP-N-acetylmuramicacid; UDP-Mpp, UDP-N-acetylmuramylpentapeptide; PEP, Phosphoenolpyruvate; UNAG, UDP- N-acetylglucosamine; UMA, UDP N-acetylmuramoyl-l-alanine; HTS, High Throughput Screening; PDB, Protein Data Bank; MD, Molecular Dynamics; SAR, Structural Activity Relationship; MIC, Minimum Inhibitory Concentration

Graphical abstract

Image 1

Highlights

  • Increasing resistance among bacterial pathogens is a major problem worldwide.

  • MurD enzyme is a novel target for drug discovery.

  • MurD enzyme undergoes conformational changes during catalytic reaction.

  • Many new inhibitors against MurD enzyme are identified by in-silico methods.

  • Bacterial membrane barrier is major challenge for drug development.

1. Introduction

The expeditious emergence of antibiotic resistance strains within microbes because of the progressive and extensive utilization of antibiotics has been one of the major concerns of the healthcare system across the globe (Klugman and Black, 2018). It has jeopardized the traditional means of successful prohibition and cure of a range of infections caused by various pathogens (Li and Webster, 2018). World Health Organization (WHO) has stated antimicrobial resistance - as one of the most high-priority threats of the current time and has asked to submit the antimicrobial surveillance reports from different countries in 2020 for input to its Global Antimicrobial Resistance and Use Surveillance System (GLASS) (www.who.int). In the contemporary scenario, there is an intense demand for the development of advanced inhibitors with an innovative mode of action Liu et al. (2019). The existence of a trivial number of efficacious therapeutic targets has resulted in an inadequate number of antibacterial agents scare to deal with escalating challenges of multi-drug resistance among bacterial pathogens (Liu et al., 2017). In this context, for the development of novel antibacterial agents, screening of a large number of compounds against newer targets will surely play a pivotal role.

The enzymes catalyzing the various steps of bacterial cell wall biosynthesis have been one of the most substantiated targets for the discovery of novel drugs. (El Zoeiby, Sanschagrin and Levesque, 2003). The bacterial cell wall is made up of peptidoglycan polymer which acts as mechanical endurance in addition to supporting the cell exterior efficiently (Barreteau et al., 2008). Apart from being indispensable, peptidoglycan is exclusively found in the bacterial world, contriving it an appropriate target for the design and development of novel antibacterial agents to target critical bacterial biosynthetic pathways (Vollmer et al., 2008). The structure of peptidoglycan consists of linear chains of alternate units of N-acetylglucosamine and N-acetylmuramic acid (Sibinelli-Sousa et al., 2021). These are cross-linked by small pentapeptides that are attached to muramyl residues directly or through other short peptides - forming a mesh-work. (El Zoeiby, Sanschagrin and Levesque, 2003). The biosynthesis of peptidoglycan has been well characterized in recent literatures (Ogasawara and Dairi, 2021). The biosynthesis of peptidoglycan takes place in three sections of the cell i.e., cytoplasm, membrane, and periplasm, catalyzed mostly by enzymes acting in sequential order (Miyachiro et al., 2019).. Lipid II is the major constituent of peptidoglycan that is synthesized through the activity of Mur enzymes in the cytoplasm of the cell (Miyachiro et al., 2019). After synthesis, the enzyme called flippases catalyze the movement of Lipid II to the flip side of the bacterial membrane where transpeptidation and glycosyltransferase reaction are carried out through the activity of penicillin binding proteins (pbp) (Miyachiro et al., 2019).

UDP-N-acetylglucosamine (UDP-GlcNAc) is the starting precursor for the cytoplasmic stages of peptidoglycan synthesis resulting in the formulation of UDP-MurNAc, the reaction being catalyzed by enzymes, UDP-N- acetylglucosamine enolpyruvyl transferase (MurA) and UDP-N-acetylenolpyruvylglucosamine reductase (MurB) (Miyachiro et al., 2019). MurA brings about the transference of the enolpyruvyl group from its substrate phosphoenolpyruvate (PEP) to UDP-N-acetylglucosamine (UNAG) resulting in the formation of UDP-N-acetylglucosamine enolpyruvate (UNAGEP) (Miyachiro et al., 2019). The succeeding step involves the reduction of UNAGEP through the activity of MurB by utilizing NADPH, resulting in the formation of UDP-MurNAc(Barreteau et al., 2008). The successive addition of peptides takes place by the activity of four ATP-dependent ligases, MurC, MurD, MurE, and MurF (Jha et al., 2020). These enzymes catalyze the addition of L-Ala, D-glutamic acid (D-Glu), meso-diaminopimelic acid (m-DMPA) (or L-Lys), and D-Ala-D-Ala respectively to UDP-N acetylmuramic acid (UDP-MurNAc) (M. A. Azam and Jupudi, 2019).

Mur ligases (C, D E & F) present as one of the appealing groups of targets that can be employed for the discovery of newer drugs (Hrast et al., 2014). Since the last decade, a wide range of studies has been done on Mur ligases, resulting in the finding of a novel and varied group of inhibitors. All the Mur ligases have a common mechanism of action and an organized kinetic mechanism (Hrast et al., 2019). Also, all the Mur ligases have a highly conserved ATP binding site having similar sequences which varies in the range of 22–26%. Other common features among Mur ligases include the presence of a P-loop having an abundance of glycine residues and varied residues like glutamic acid and histidine involved in the regulation of Mg2+ ions (El Zoeiby et al., 2003). Despite these similarities, there are differences in the configurational topology and arrangement of residues present in the catalytic site of MurD from diverse groups of bacterial species like Staphylococcus aureus, Borellia burgdoferi, Escherichia coli (E. coli), Mycobacterium tuberculosis and, many more (M. A. Azam and Jupudi, 2020).

MurD enzyme along with other Mur ligases plays an important role in the synthesis of peptide stem of N-acetylmuramic acid during cell wall synthesis. The structure and mechanism of action of the MurD enzyme have been characterized thoroughly (Zdouc et al., 2018). It is the second enzyme in the series of Mur ligases that catalyzes the joining of D-glutamic acid residue to its substrate UDP-MurNAc-l-Ala (UMA) which includes acyl-phosphate and tetrahedral intermediates (El-Sherbeini et al., 1998). MurD enzyme is highly specific for its substrate D-glutamic acid and its homologue is not present in mammalian cells making it an excellent target for the design of novel inhibitors (Perdih et al., 2014).

High throughput virtual screening (HTS) of compounds for drug discovery has entrenched with the exploration of bacterial genome sequence information in the earlier stages of the 1990s along with the accessibility of substrates and enzymes taking part in earlier steps of cell wall biosynthesis (Bugg et al., 2011). Computer-assisted drug discovery has become a leading technology in the modern drug development process. This procedure helps in making effective and efficient use of chemical modifications. Structure-based molecular docking particularly employs molecular docking procedures (Talevi, 2018). For the identification and development of lead compounds against the potential targets for drug discovery, there has been a gradual increase in the use of computer-aided drug design methods. (Turk et al., 2009). Based on binding sites, molecular docking includes virtual screening of large chemical libraries to provide potential drug candidates. Molecular simulations give details about the structural and thermodynamic characteristics of target proteins on various levels that help in recognizing drug binding sites and illustrating the mechanism of action of the drug (Lin et al., 2020).

In the past several comprehensive reviews demonstrating crucial features of the MurD enzyme along with advances made in the development of inhibitors have been published (M. A. Azam and Jupudi, 2020; Šink et al., 2013). The present review gives a comprehensive insight into the structural and functional characteristics of the MurD enzyme and gives an information about the various structures of the MurD enzyme from different bacteria developed and inducted into Protein Data Bank so far along with the recent development of inhibitors against MurD enzyme with an emphasis on in-silico methods.

2. Genetic aspects and regulation of MurD enzyme

The D-glutamic acid adding enzyme (MurD enzyme) is encoded by the MurD gene. This gene is found to be positioned in the 2-min region of the E. coli genome which contains an assemblage of genes of pbpB (penicillin-binding protein B) to envelope A (envA). The order of genes in this region is pbpB-murEmurF-X-murD-Y-murG where X and Y chromosomal fragments code for unknown proteins and E and F genes are coupled together. Earlier MurD enzyme was contemplated to be a product of MurG gene but later it was found that MurD gene was positioned 2.5 ​kb upstream of murG gene (Mengin-Lecreulx et al., 1989). This 2-min region in E. coli is assigned as mra (from murein A)cluster. Seven peptidoglycan synthesizing (murein) genes including Mur ligases, mraY and ddl are located in this cluster along with genes associated with cell division (fts genes) and genes for synthesis of lipopolysaccharide (envA) (Hara et al., 1997). In Mycobacterium tuberculosis, the location of MurD gene is also reported to be present in a cluster of genes positioned near genes like ftsW that are involved in cell division. There is 64% homology within MurD gene of E. coli and M. tuberculosis (Thakur and Chakraborti, 2008). Gram-negative bacteria E. coli and Haemophilus influenzae have a conserved series of genes in the entire mra cluster. However, in Gram-positive bacteria, there are slighter variations in the position of genes. The pbp1 succeeds mraY in Staphaureus, Enterococcus faecalis, and Streptococcus pyogenes, while the series of genes murD, murG, divIB, ftsA, ftsZ remains unchanged in E. faecalis, E. hirae, and St.. pyogenes (Watanabe et al., 1997). Location of Mur D gene in Staph aureus was displayed by sequence analysis and was found to be positioned in an array of genes present in the order of pbp1 (encoding penicillin-binding protein 1), mraY, murD, divIB, ftsA, ftsZ, orf, divIVA, ileS (encoding isoleucyl tRNA synthetase). Compared to E. coli, these genes were supposed to be part of the same operon as were transcribed by the identical portion of DNA and carried short intergenic sections (El-Sherbeini et al., 1998). Three genes present in the 4.4 ​kb region of Bacillus subtilis chromosome-map between the distal portion of spoVD promoter sequence and start of spoVE gene were found to have sequence homology with the genes murE, mraY and murD present in E. coli (Daniel and Errington, 1993). Several genes present in the 133″ regions of B. subtilis are known to have functional similarity with the cluster of genes present in the E. coli 2min region. B. subtilis chromosome apart from having a similar series of genes to that of E. coli, differs in the absence of three genes and presence of more comprehensive intergenic regions in B. subtilis genome as compared to E. coli (Daniel and Errington, 1993).

A single mra promoter controls the transcription of genes contained in mra operon of E. coli including the murD gene. Studies on mutant E. coli strains have shown that reduced expression of murD gene in the mra promoter results in lysis of the bacterial cell displaying the essential nature of MurD gene for bacterial survival (Hara et al., 1997). Serine/threonine protein kinases were found to have a potential role in the regulation concerning biosynthetic machinery of peptidoglycan in mycobacteria as were found to phosphorylate the MurD enzyme. The concentration of MurD enzyme and incubation time were found to play a major role in the phosphorylation reaction catalyzed by the labelled Serine/threonine protein kinase (PKnA) (Thakur and Chakraborti, 2008).

MurD gene of Staph aureus contains an open reading frame of 449 amino acids (El-Sherbeini et al., 1998). A significant level of homology exists between MurD protein from Staph. aureus and that of the other bacteria i. eE.coli (54%), H. influenzae (55%), B. subtilis (65%) and Strep. pyogens (66%). Numerous residues present in the homologous regions of MurD enzyme are conserved among various groups of bacteria, which also includes the region of the C-domain containing the ATP binding site (El-Sherbeini et al., 1998).

All the base sequences in the mra region of 12 ​kb chromosomal portion containing genes for Mur ligases E, F and D, mra Y, and MurG have been elucidated (Fig. 1.) (Ikeda et al., 1990, Ikeda et al., 1990). In E. coli, MurD enzyme encoding gene is about 2.6 ​kb and its location on chromosome map is in between the murF and ftsW genes at 2min region (Genebank ID 944818). Elucidation of sequences showed the occupancy of two open reading frames in this region, one encoding for Mur D enzyme and another is open reading frame Y located downstream to MurD. The Open reading frame of MurD consists of 1314 bp and encodes a protein of 438 amino acids with a molecular weight of 46938 (Ikeda et al., 1990).

Fig. 1.

Fig. 1

Mechanism of action of MurD enzyme.

In multi drug resistance strains of Enterococcus faecalis, antibiotic resistance genes are present in 3 clusters namely C1, C2 & C3. The 6 mur enzymes murAB, murB, murC, murD, murE and murF are present in Clusture C1 and play a role in peptidoglycan biosynthesis (Naha, A et al., 2020).

3. Functional aspects of mur D enzyme

The crystal structures of MurD enzymes with various ligands have been elucidated from various bacteria e.g. E. coli (Bertrand et al., 1999), Thermotoga maritime (Favini-Stabile, Contreras-Martel, Thielens and Dessen, 2013), Streptococcus agalactiae (serogroup V) by Stein et al. in 2010. Apart from that, several structures have been generated by homology modeling of various pathogenic bacterial species Staph aureus (M. A. Azam and Jupudi, 2019), Leptospira interrogans (Amineni et al., 2010)) to develop potential inhibitors by utilization of in-silico tools. But the most earlier and extensive work has been done on E. coli MurD in last couple of decades (Bertrand et al., 1997; Humljan et al., 2008; Kotnik et al., 2007). MurD enzyme (UDP-N-acetylmuramyl-l-alanine:d-glutamate ligase), has a molecular weight of 46,973 ​Da and is the second enzyme in the series of Mur ligases (M. A. Azam and Jupudi, 2020). MurD brings about the addition of D -glutamic acid (d-Glu) residue to its substrate UDP-N-acetylmuramyl-l-alanine (UMA) which leads to the creation of a peptide bond joining the amino residue of D-glutamic acid and the carboxyl group of UDP-N-acetylmuramyl-L-alanine.The reaction results in the utilization of an ATP molecule with the production of an ADP and release of the orthophosphate group (Walsh et al., 1999).

Resolution of crystal structures of associations of MurD enzyme from E. coli with several ligands and their products like quaternary complex of MurD enzyme with UMA, ADP and Mg2+ ion and Mn2+ion, product ADP and UMA and binary complex of the enzyme alongside the product UDPN-acetylmuramoyl-L-alanine-D-glutamate (UMAG) were studied in order to understand the mechanism of action (Bertrand et al., 1999). The mechanism of catalysis involves the initial phosphorylation of carboxylic acid at C-terminal position of substrate UMA by the gamma phosphate group of ATP with the generation of acyl phosphate intermediate. Nucleophilic attack by the amino group of the inbound D-Glutamic amino acid on acyl phosphate results in the formation of a high-energy tetrahedral intermediary that is finally converted to the amide product and subsequently inorganic phosphate is released (Fig. 1.) (Bertrand et al., 1999; Humljan et al., 2008). The primary phosphorylation of the substrate UMA takes place in the cleft present in between the central and C-terminal domains. Entrance of reactive part of UMA into the cleft occurs close to the N-terminal domain and the ATP molecule enters from the opposing end (Hrast et al., 2019).

Two bivalent cations (Mn2+& Mg2+) are needed by the MurD enzyme to transmit a phosphoryl group amongst a pair of anionic substrates (Bertrand et al., 1999). These divalent cations are not required for the binding of the substrates UMA and ADP, but play a crucial role in the ligase action of the MurD enzyme (Kotnik et al., 2007).

The principle residues of the MurD enzyme of E. coli which take part while interacting with the substrate UMA involves amino acid residues Leu15, Thr16, Asp35, Thr36, Arg37, Gly73, and Asn138, while His183 interacts with Mg2+(Bertrand et al., 1997, 1999, 2000; Bertrand et al., 1999). At the same time, ADP interacts with Gly114, Lys115, Ser116, Thr117, Asn271, Arg302, and Asp317 residues. Interaction of D-glutamic acid includes residuesThr321, Lys348, Ser415, Leu416, and Phe 422 (Bertrand et al., 1999) (Table 1).

Table 1.

Amino acid residues present at various domains of MurD enzyme.

Domain Binding substrate Amino acid Residues References
N-terminal domain UMA Val18, Thr19, Asp39, Asp40, Gly75, Asn147, Gln171 &His192 Kotnik et al., 2007
Central domain ATP Gly123, Lys124, Thr125, Thr126, Glu166, Asp283, and Arg314 Mustafa Alhaji Isa.,2019
C-terminal domain D-Glutamic acid Arg382, Ser463, and Tyr470 Mustafa Alhaji Isa.,2019

Closed configuration of MurD crystal structure obtained by interaction with enantiomeric Glutamic acid derivatives showed an 1800 turnover of Leu13-Gly14 and Pro41-Gly42 bonds resulting in a small movement of N-terminal domain from Leu13 to Val150. Minute contortion of the central domain also takes place particularly at Ile139 and Gly140 amino acids as a result of the binding of inhibitors in the enzyme active site (Kotnik et al., 2007). After hydrolysis of ATP molecule, the resulting ADP molecule binds to P-loop of the enzyme molecule, consisting of residues from 108 to 116 forms a part of mononucleotide -binding fold. The ADP molecule binds within an area located in the middle of the central and C-terminal domains. The studies on D-glutamic acid-based inhibitors have, shown that most of the hydrogen bonds with the amino acids present in the active site of the MurD enzyme are formed by the D-Glu portion of the inhibitor that inhabits the binding site of the D-Glutamic- acid region and the heterocyclic ring occupying the uracil-binding region (Tomašić et al., 2011). The MurD enzyme is specific for its substrate D-Glutamic acid which is displayed by its interaction with its product UMAG (PDB 4UAG), in which the carboxylic group at alpha position of D-Glu forms hydrogen bonds with Thr321 residue and interacts in a charge based manner with nitrogen of Lys348 residue while the γ-carboxylate is hydrogen-bonded to amino acid residues Ser415 and Phe422 (Humljan et al., 2008). MurD enzymes from gram-negative bacteria, E. coli, and H. influenzae exhibit feedback inhibition by the substrate UMA when the concentration exceeds the 15 and 30 ​μM level while MurD enzymes from gram-positive bacteria E. faecalis ​and ​S. aureus ​have little effect on UMA concentration (Table 2.) (Walsh et al., 1999).

Table 2.

Relative efficiencies of MurD enzymes from various bacterial species.

Organism KmATP (μM) Km UMA (μM) Km D-Glu (μM) References
Strep. pneumoniae (MurD) 2000 (Approx) 96 ​± ​39 190 ​± ​26 H.Barreteau et al., 2012
Borellia burgdoferi (MurD) 53 ​± ​12 63 ​± ​30 110 ​± ​29 H.Barreteau et al., 2012
Myco. tuberculosis (MurD) 710 ​± ​290 340 ​± ​10 700 ​± ​180 H.Barreteau et al., 2012
E.coli (MurD) 97 ​± ​9 7 ​± ​0.6 42 ​± ​5 M.Simčič et al., 2014
Staph.aureus (MurD) 5400 41 100 H.Barreteau et al., 2012
E.faecalis (MurD) 47 ​± ​4 36 ​± ​7 118 ​± ​14 Walsh et al. (1999)
Haemophilus influenzae (MurD) 102 ​± ​6 8 ​± ​4 169 ​± ​20 Walsh et al. (1999)

4. Structural features & physiochemical properties of MurD

So far, 25 crystal structures of the MurD enzyme have been elucidated and submitted to the PDB (Table 3). The crystal structures from many bacterial species likeE.coli (Zidar et al., 2011) (Šink et al., 2016)Thermotoga maritima (Favini-Stabile, Contreras-Martel, Thielens and Dessen, 2013), and Streptococcus agalactiae serogroup V by Stein et al., 2009) in both open and closed forms have been resolved so far (Fig. 2.). Considerable resemblances were observed in the domain organization of these crystal structures. Three globular domains i.e. N-terminal domain, central domain and C-terminal domain constitute the binding pocket of MurD enzyme (Bertrand et al., 1997). N-terminal domain is attributed for binding of UDP component of UMA. The central domain acts as ATP binding region and is conserved in the entire Mur enzyme family. The C-terminal domain takes part in the binding of D- Glutamic acid. The cleft between the central and C-terminal domains forms the active site of the MurD enzyme (M. A. Azam and Jupudi, 2017). N-terminal domain involves amino acid residues from 01 to 93. It is composed of five lateral strands of B-sheet encircled by a quartet of α-helices. The C-terminal domain comprehend 94 to 298 amino acids and is composed of a β-sheet of parallelly organized six strands enclosed by seven α-helices and an antiparallel β-sheet consisting of three strands (Bertrand et al., 1999).

Table 3.

PDB entries of MurD enzyme.

S. No PDB Entry Ligand/s Resolution (Ao) Organisms References
1. 1UAG UMAa, SO4 1.95 E.coli Bertrand et al. (1997)
2. 2UAG UMA,ADPb, Mg +ion 1.7 E.coli Bertrand et al. (1999)
3. 3UAG UMA,ADP, EPEc, Mg +ion 1.77 E.coli Bertrand et al. (1999)
4. 4UAG UMA, sulphate ion 1.66 E.coli Bertrand et al. (1999)
5. 1EEH UMA 1.9 E.coli Bertrand et al. (2000)
6. 1E0D Sulphate ion 2.4 E.coli Bertrand et al. (2000)
7. 2JFF LK2d,SO4 1.89 E.coli Kotnik et al., 2007
8. 2JFG UMA,ADP,SO4 1.52 E.coli Kotnik et al., 2007
9. 2JFH LK1e,SO4 1.97 E.coli Kotnik et al., 2007
10. 2UUP LK4f,SO4 1.88 E.coli Humljan et al., 2008
11. 2JFH LK1,SO4 1.97 E.coli Kotnik et al., 2007
12. 2VTE LK4,SO4 2.2 E.coli Humljan et al., 2008
13. 2VTD LKMg,SO4 ion 1.94 E.coli Humljan et al., 2008
14. 2UUO LK3h,SO4 2.5 E.coli Humljan et al., 2008
15. 2WJP D17i, azide ion, Cl ion, DMSj 1.6 E.coli Tomašić et al., 2010
16. 2X5O VSVk,SO4,SO3,Azide, Cl ion 1.46 E.coli Zidar et al. (2010)
17. 3LK7 Cl & SO4 ion 1.5 Strep.agalactiae Stein et al., 2009
18. 2Y68 DMS, Azide ion & Cl ion 1.49 E.coli Tomašić et al., 2011
19. 2Y66 NO4, sulphate ion, sulphite ion, DMS,Cl 1.49 E.coli Zidar et al. (2011)
20. 2Y67 N21l, sulphate ion 1.85 E.coli Zidar et al. (2011)
21. 2Y10 DMS,SO4 1.49 E.coli Tomašić et al., 2012
22. 4BUC Glycerol,PO4,PO3, Cl ion,NH4+ion 2.17 T. maritima Favini-stabile et al. (2013)
23. 2XPC 051m,DMS,SO4,Cl ion 1.49 E.coli Sosic et al.,2013
24. 5A5E UMA,ADP, Malonate ion 1.9 E.coli Sink et al.,2016
25. 5A5F UMA,ADP 1.9 E.coli Sink et al.,2016
a

UMA: UDP –N-acetylmuramoyl-L-alanine.

b

UDP:Uridine -5′-Diphosphate.

c

EPE: 4-(2-Hydroxyethyl)-1-Pipeazine ethanesulphonic acid.

d

LK2: N-[(6-Butoxynapthalene-2-YL)sulfonyl]-D-Glutamic acid.

e

LK1:N-[(6-Butoxynapthalen-2-yl)sulfonyl]-L-Glutamic acid.

f

LK4: N-({6-[4-cyanobenzyl)oxy]Naphthalen-2-yl}phonyl)-D-Glutamic acid.

g

LKM:N-({6-[4-cyano-2-fluorobenzyl)oxy]Naphthalen-2-yl}sulfonyl)-D-Glutamic acid.

h

LK3: N-{[6-(Pentyloxy)Naphthalen-2-yl]sulfonyl}-D-Glutamic acid.

i

D17: N-({3-[({4-[(Z)-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene]methyl]phenyl}amino)methyl]phenyl}carbonyl)-L-Glutamic acid.

j

DMS:Dimethyl sulphoxide.

k

VSV: N-({3-[({4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidine)methyl]phenyl}amino)methyl]phenyl}carbonyl)-D-Glutamic acid.

l

N21: (2R)-2-[[4-[[4-(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidine)methyl]phenoxy}methyl]phenyl}sulfonylamino]pentanedioic acid.

m

051: (1R,3R,4S)-4-[({6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl}sulfonyl)amino]cyclohexane-1,3-dicarboxylic acid.

Fig. 2.

Fig. 2

Open structures of MurD enzyme from E. coli (PDB:1E0D,1EEH).

During the catalytic reaction of MurD enzyme, there are successive changes in the morphology of these domains from open to closed states through an intermediate semi-closed position. Obliteration of domain motion of each ligand takes place following each stage of ligand binding. During the catalytic reaction, the apo form of the MurD enzyme exhibits twisting as well as opening, and closing of its domains. Twisting is repressed as a result of the binding of ATP while binding of inhibitor results in suppression of open-closed method (Nakagawa et al., 2021). E. coli MurD enzyme shows two open configurations, one in the free state and the other bound to its substrate UMA (Šink et al., 2016). Based on NMR spectroscopy and X-ray crystallography studies on the manners of binding of inhibitors to MurD catalytic site a new crystal structure of MurD (2XPC) was resolved with the inhibitor 4-aminocyclohexane-1,3-dicarboxyl.A charge-based interaction was observed by the contribution of the carboxyl group placed at position 3 in the cyclohexyl ring with the nitrogen atom of Lys348 (Sosič et al., 2011).

During the catalysis reaction, the MurD enzyme exhibits a semi-closed form. The MurD enzyme undergoes several changes in its shape because of the attachment of its ligand that in turn controls ligand binding sequence and also regulates its binding affinity to the succeeding ligand (Saio et al., 2015). C-domain of MurD enzyme assumes most distinct conformations compared to other domains. The C-terminus of the MurD enzyme exhibits the most flexibleness and does not collude with the central domain and in the same asymmetric section displays two non-identical configurations (Favini-Stabile et al., 2013).

So far, work conducted on crystallographic structures of MurD enzyme suggested a possible configurational drift of the C- terminal domain to the center of the structure. This change is due to binding of the ligand molecule, resulting in the closing of the enzyme (Bertrand et al., 1999, 2000). In open structures of MurD enzyme (pdb:1EEH) greater energy is required for closure of the C-terminal domain when its location is outside the plane of the central and N-terminal domain as compared to the open crystal structure when the C-terminal domain is restricted within the plane of these domains (PDB:1EOD) (Perdih et al., 2014).

The NMR spectrum has shown that domain 3 of the MurD enzyme undergoes drastic conformational changes during its catalytic process. During its Apo state, the MurD enzyme shows a shifting from open to close form (Saio et al., 2015). In contrast, the closed configuration of the enzyme is sustained by coupling of the ligand molecule (PDB IDs 2X5O and 2JFF). The progression in which the various ligands bind the MurD enzyme includes the initial binding of ATP in the ubiquity of Mg2+ that is followed by the binding of the UMA, succeeded by the hydrolysis of the ATP molecule. At the end, binding of D-Glutamic acid takes place (Saio et al., 2015).

E.coli MurD enzyme showed sequence identities of 31% with Bacillus subtilis and 62% with Haemophilus influenza respectively (Bertrand et al., 1997). Conserved amino acid sequences are also reported between E. coli and Staphylococcus aureus (Bouhss et al., 1999). Amino acid sequence identity was said to be 31% between MurD from E. coli (PDB ID 1EEH, 1UAG & 2JFF) and that from Mycobacterium tuberculosis while similarity was at 45%. (Barreteau et al., 2012). The crystal structure of the MurD enzyme from E. coli (PDB ID 2JFH) was considered most suitable for homology modeling of M. tuberculosis MurD enzyme. The crystal structure displayed 45% sequence similarity and 31% sequence identity with the query sequence. (Shinde et al., 2021). In Xanthomonas oryzae, MurD2 enzyme (X00_1320) was identified as the first MurD enzyme that was able to ligate L-Glutamic acid (Fig. 3). This MurD2 displayed 26% identity with canonical MurD enzyme from E. coli. (Feng Ruoyin, 2019).

Fig. 3.

Fig. 3

Amino acid sequence comparison: Multiple sequence alignment of MurD from E. coli (Accession no. A0A4C3NEP4), M. tuberculosis (Accession no. A5U4I2), Bacillus subtilis (Accession no. Q03522), Thermotoga maritima (Accession no. Q9WY76), Streptococcus agalactiae (Accession no. Q8E6P1), Borrelia burgdorferi (Accession no. O51532), Staph. aureus (Accession no. P0A091), Leptospira interrogans (Accession no. Q8F7V4) Streptococcus pneumoniae (Accession no. C1CD51), Haemophilus influenzae (Accession no. Q4QLG0). (output of Clustal Omega) (MurD Accession no. from www.unipro.org).

MurD from E. coli is closely related to MurD from Haemophilus influenza and belongs to a single clade. Both are closely related to the Mycobacterial MurD enzyme in terms of phylogeny and all are part of a single ingroup. MurD from E. coli is distantly related to all the other organisms tested (Fig. 4).

Fig. 4.

Fig. 4

Phylogentic tree of MurD enzyme from different bacterial species: MurD E. coli (Accession no. A0A4C3NEP4), MurD M. tuberculosis (Accession no. A5U4I2) MurD Bacillus subtilis (Accession no. Q03522), MurD Thermotoga maritima (Accession no. Q9WY76), MurD Streptococcus agalactiae (Accession no. Q8E6P1), MurD Borrelia burgdorferi (Accession no. O51532), MurD Staph. aureus (Accession no. P0A091), MurD Leptospira interrogans (Accession no. Q8F7V4)M, urD Streptococcus pneumoniae (Accession no. C1CD51), MurD Haemophilus influenzae (Accession no. Q4QLG0). (output of Clustal Omega) (Accession no. from www.unipro.org).

4.1. Physiochemical properties of MurD

Specific activities of the MurD enzyme from gram-positive bacteria E. faecalis and Staph aureus were found to be 2 to 6 times higher than their gram-negative counterparts from E. coli and H. influenza.In terms of efficiency MurD from Staph aureus was less efficient when compared with MurD from E. faecalis, E. coli, and H. influenza (Walsh et al., 1999). Studies on the effect of monovalent ions like NH4+ and K+ displayed these ions to increase the activity of MurD enzyme in gram-negative organisms which may be attributed to their role in conformational changes in proteins and stabilization of various reaction intermediates. But these monovalent cations displayed little or no effect on gram-positive organisms which was attributed to the thicker cell wall and subsequent higher demand for peptidoglycan precursors (Takahashi et al., 1984; Wedler and Ley, 1993). The transition state analog [1 (6-uridine diphospho)hexanamido](2,4-dicarboxybutyl) phosphinate was found to have an inhibitory effect on Mur D enzyme from all groups of bacteria probably due to similar transition state conformation. Most of the MurD enzymes from various groups of bacteria operate at optimum pH of 8–9.2. But studies on MurD from Mycobacterium tuberculosis displayed it to function best at alkaline pH. Further studies displayed that MurD orthologs from Borrelia burgdorferi and M. tuberculosis are less active (in terms of Km & Vmax) when compared with that from Staph aureus, Streptococcus pneumonia, and E. coli owing to slow growing nature of these bacteria (Barreteau et al., 2012).

In all the bacterial species, the Mur D enzyme is located in the cytoplasm of the cell (Table 4.) where it plays an important role in the biosynthesis of the peptidoglycan layer and a few bacteria undergo post-translational modification.

Table 4.

Properties of MurD enzyme from different bacterial species.

MurD Accession no. Length (amino acids) Mass (Dalton) Subcellular Location References
MurD E.coli A0A4C3NEP4 375 40,036 Cytoplasm https://www.uniprot.org/
MurD aM.tuberculosis A5U4I2 496 50,354 Cytoplasm https://www.uniprot.org/
MurD Bacillus subtilis Q03522 451 49651 Cytoplasm https://www.uniprot.org/
MurD Thermotoga maritima Q9WY76 430 49154 Cytoplasm https://www.uniprot.org/
MurD Streptococcus agalactiae Q8E6P1 451 48972 Cytoplasm https://www.uniprot.org/
MurD Borrelia burgdorferi O51532 451 51054 Cytoplasm https://www.uniprot.org/
MurD Staph.aureus P0A091 449 49844 Cytoplasm https://www.uniprot.org/
MurD leptospira interrogans Q8F7V4 463 51298 Cytoplasm https://www.uniprot.org/
MurD Streptococcus pneumoniae C1CD51 450 48356 Cytoplasm https://www.uniprot.org/
MurD Haemophilus influenza Q4QLG0 437 47931 Cytoplasm https://www.uniprot.org/
a

Post translational modification/processing: Mycobacteria tuberculosis MurD is phosphorylated by PknA.

PknA, a eukaryotic type serine/threonine kinase that is encoded in the genome of Mycobacterium tuberculosis was found to transphosphorylate, mycobacterial MurD. The finding gave the possibility of MurD being a substrate for the enzyme PknA and indicated that the kinase might be playing a role in the regulation of cell division and peptidoglycan biosynthesis (Thakur and Chakraborti, 2008). Overproduction of MurD ligase was observed in E. coli strains containing recombinant plasmids having the MurD gene under the control of lac or PR promoter (Pratviel et al., 1991).

5. Inhibitors of MurD

Among the ATP-dependent ligases involved in the synthesis of bacterial peptidoglycan, the MurD enzyme is considered one of the potential targets for the development of novel antibacterial agents. Several structures of MurD enzyme with co-crystallized ligands have been elucidated (Bertrand et al., 1997, 1999, 2000; Bertrand et al., 1999; Kotnik et al., 2007) providing the basis for the design and development of novel inhibitors. In the last two centuries, significant advancements have been made in understanding the structural properties and mechanism of action of MurD from several bacteria (E.coli, Staph aureus, Strep. pneumoniae, Leptospira interrogans, Borellia burgdoferi) and studies on orthologs of MurD from various pathogenic species have been done (Barreteau et al., 2012; Walsh et al., 1999). Several compounds acting as potential inhibitors of MurD, from the category of natural and synthetic components have been identified by structural activity relationship (SAR) and HTS methods (Table 6). But till date, none of the compounds have been successful for clinical use against the MurD enzyme.

Table 6.

Significant inhibitors of MurD enzyme identified so far.

Compounds Mode of Inhibition/MOAa IC50b (uM) MIC (ug/ml) References
N-sulfonyl-D- & L-Glu derivatives Competitive inhibition towards D-Glutamic acid 280 & 710 Nd Kotnik et al. (2007)
Napthalene-N-sulphonyl -D-glutamic acid derivatives by interaction of alpha & gamma carboxylate gps of glutamate residue with a.a residues of enzyme 80–600 Nd Humljan et al., 2008
Peptide inhibitors Binds to active site of enzyme 140 Nd Bratkovič et al., 2008
5-benzylidenerhodanine moeity (Glutamic acid based inhibitors) D-Glu analogues 174 & 206 Nd Tomašić et al., 2010
5-benzylidenerhodanine- and 5-benzylidenethiazolidine2,4-dione-based compounds Competitive inhibition towards D-Glutamic acid 45–206 >128c Zidar et al. (2010)
5-benzylidenethiazolidin-4-one moiety Binds to active site of enzyme 3–7 Low activityd Tomašić et al., 2011
5-benzylidenethiazolidin-4-one inhibitors by H-bonding with active site residues, analogue of UMAG 28 128e Zidar et al. (2011)
thiazolidine-4-one-based compounds transition state analogues 6.4–180 8f Tomašić et al., 2012
2-oxoindolinylidene based inhibitor competitive inhibition towards product UMA ne 128g Simčič et al., 2014
Inhibitors from zinc database interacts with central domain of enzyme 28 50uMh Samal et al.,2015
benzothiazol-2-ylcarbamodithioate vander wall interactions with active site residues 13.37 2–64i Jupundi et al.,2019
H5 (EnamineT1827917) interaction with active site residues 7 128,128,256j Azam et al. (2019)
ATP-dependent Kinase inhibitors competitive inhibition towards D-Glutamic acid 104 Inactivek Hrast et al. (2019)
phenoxyacetohydrazide derivatives vander wall interactions with active site residues 35.80 ​μM 64,128l Jupundi et al.,2020

n.e not explained, n.d. not determined, UMAG:UDP N-acetylmuramoyl-l-alanine,D-Glutamic acid, UMA:UDP N-acetylmuramoyl-l-alanine.

a

MurD activity was assayed by the detection of the orthophosphate generated during the reaction based on the colorimetric Malachite green method.

b

The detrmination of MIC values were done on the basis of National Committee for Clinical Laboratory Standards (NCCLS).

c

MIC values have been determined againstE. coli ATCC 25922, P. aeruginosa 27853, S. aureus ATCC 29213, and E. faecalis ATCC 2921.

d

MIC values have been determined against Staphylococcusaureus and Enterococcus faecalis.

e

MIC values have been determined against S. aureus ATCC 29213, E. faecalis ATCC 29212.

f

MIC values have been determined against Staph aureus& MRSA.

g

MIC values have been determined against Haemophilus influenzae (ATCC49247) and Enterococcus faecalis (ATCC 29212).

h

MIC values have been determined against Salmonella typhimurium.

i

MIC values have been determined against S. aureus NCIM 5021 and S. aureus NCIM 5022.

j

MIC values have been determined against S. aureus NCIM 5021, S. aureus NCIM 5022, and methicillin resistant S. aureus (MRSA strain 43,300).

k

MIC values have been determined E. coli&Staph aureus.

l

MIC values have been determined S. aureus NCIM 5022, methicillin resistant S. aureus ATCC 43300.

In the current scenario, with the advent of computer-aided drug design methods (CADD) in combination HTS, several inhibitors forthe MurD enzyme have also been identified and designed using in-silico methods while screening large compounds libraries (M. A. Azam and Jupudi, 2017, 2019; Simčič et al., 2014).

5.1. Second-generation sulfonamide inhibitors

Binding means of a group of sulphonamide derivatives based on naphthalene-N-sulfonyl-D-glutamic acid were studied against the E. coli MurD enzyme. In these compounds, the D-glutamic acid fraction was replaced by rigid mimics. Molecular dynamics (MD) simulation studies on these inhibitors demonstrated the role of stretching forces while the interaction of sulphonamide inhibitors with C-terminal and the N-terminal domain and these must be acknowledged while designing novel inhibitors. Also suggested flexibility of inhibitor molecule to adjust to the conformational variations of MurD enzyme. A group of sulphonamide derivatives, which were based on the N-sulfonyl-D-Gluamic acid fraction, were studied against E. coli's MurD enzyme. The interaction between these derivatives and the N-terminal and C-terminal domains was studied. Molecular dynamics (MD) simulation studies on these inhibitors demonstrated the role of stretching forces while the interaction of sulphonamide inhibitors with C-terminal and the N-terminal domain (Simčič et al., 2012).

5.2. Inhibitors obtained by structural modification of thiazolidine-4-one-based compounds

Dual inhibitors for MurD and MurE from both E. coli and Staph aureuswere designed by structural modification of thiazolidine-4-one-based compounds. The most active compound displayed an IC50 value of 8.2 and 6.4 ​μM against MurD of E. coli and Staph aureus respectively and a MIC of 8 ​μg/mL against Staph. aureus and MRSA (Tomašić et al., 2012).

The inhibitor was found to hinder the binding position of product UDP-MurNAc-L-Ala-D-Glu (UMAG). The inhibitor shows hydrophobic interactions with Leu416 residue and π−π interactions with Phe161 residue. Thr321, Lys348, Ser415, and Phe422 residues are involved in hydrogen bonding to the D-glutamic acid fraction of the inhibitor (Tomašić et al., 2012).

5.3. Naphthalene-N-sulfonyl-D-glutamic acid derivatives

A series of Naphthalene-N-sulfonyl-D-glutamic acid derivatives were identified as potential inhibitors for E. coli MurD enzyme through structural activity relationship (SAR). These compounds exhibited IC50 values in the range of 80–600 ​μM. These sulphonamides containing compounds were designed to mimic the tetrahedral intermediate state formed during the catalysis reaction of the MurD enzyme (Humljan et al., 2008) (Fig. 5.). γ-carboxylate group in D-glutamic acid derivatives were found to play a major role during the interaction with the enzyme. The carboxamide and sulphonamide series of substituent compounds were found to be inactive as compared to series containing bulky substituents of biphenyl and naphthalene, displaying IC50 values of 1720 and 810 ​μM. The series of compounds in which there was a direct attachment of naphthalene moiety to the D-Glu amino acid residue via the sulphonamide moiety, displayed inhibitory activity in contrast to those which do not have a direct contact. A three-fold increase in inhibitory activity was detected when length of side chain was increased by replacing methyl to pentyl group (590–170 ​μM). Arylalkyloxy substituents were found to be more effective as a substituted inhibitor (Humljan et al., 2008).

Fig. 5.

Fig. 5

Basic chemical structure of a sulphonamide inhibitor.

5.4. 2-Oxoindolinylidene based inhibitor

2-oxoindolinylidene based inhibitor (Fig. 6A) with a novel framework was evaluated using a steady-state kinetic mechanism against E. coli MurD enzyme. The derivative showed a competitive mode of inhibition for the substrate UMA. A MIC value of 128 ​μg/ml was obtained against Haemophilus influenzae (ATCC 49247) and Enterococcus faecalis (ATCC 29212) strains (Simčič et al., 2014).

Fig. 6.

Fig. 6

6A: Chemical structure of 2-oxoindolinylidene based inhibitor; 6B. Chemical structure of 2- Thioxothiazolidin-4-one based inhibitor.

NMR studies showed that unlike transition state analogues, the inhibitor interacted with the N-terminal and central domain, and there was no interaction with the C-terminal domain of the enzyme. As a result, its binding was unaffected by domain movements. 2-oxoindolinylidene ring was found to be located in the uracil-binding site. Hydrophobic interactions were mainly involved in the stability of the enzyme-inhibitor complex as demonstrated by MD simulation suggesting studies for the de novo examination of new structures with more powerful binding affinities (Simčič et al., 2014).

5.5. Marine natural products as inhibitors

A marine natural product library was screened for potential inhibitors against modeled Staph aureus MurD enzyme with molecular docking and simulation studies. Two compounds from seaweed database (SWMD) (http://www.swmd.co.in) showed a strong interaction within the binding pocket of the enzyme and displayed potential therapeutic effects and stable configuration with the target protein enzyme (Zheng et al., 2021). Compound 2 (46604) displayed hydrophobic interactions with amino acids Lys19 and Asn145 and hydrogen interactions with Glu166, Ser168, Lys328, and Thr330 residues. Compound 3 (46608) interacted by displaying hydrophobic interactions with Thr330 and Phe431 amino acids while Asn145, Ser168, and Lys328 residues were involved in H-bond formation (Zheng et al., 2021).

5.6. 2-Thioxothiazolidin-4-one based inhibitors

2-Thioxothiazolidin-4-one based marked as compound $1 (Fig. 6B) was studied as a potential inhibitor of homology modeled Staph aureus MurD enzyme through molecular docking and molecular dynamics studies. Major interactions between the inhibitor and MurD enzyme observed were salt bridge interactions, π-π stacking, and hydrogen bonding. Stabilization of inhibitor-enzyme complex was mainly contributed by residues Lys19, Gly147, Tyr148, Lys328, Thr330, and Phe431. Vander wall and electrostatic solvation energies were mainly involved in inhibitor binding. MD simulation showed the inhibitor and the modeled MurD enzyme to be in a stable configuration. During in-vitro validation, the compound was found to inhibit the enzyme with an IC50 value of 6.40 ​μM. Antibacterial activity assays showed the compound to be effective against commercial Staph. aureus and MRSA strains displaying MIC values of 8 ​μg/ml (M. Azam, Jupudi, Saha and Paul, 2019).

Molecular simulation studies on the inhibitor $1 showed that its configurational flexibilities were mainly dependent on rotations of a single bond around the C6H4–CO–NH-,C6H4–CH2–NH–C6H4- group along with the structural features of D-glutamic acid. As 2-thioxothiazolidin-4-one ring has a non-significant contribution towards the binding process, a series of new inhibitors (D1, D2, D3 & D4) (Fig. 7) were designed. These were prepared by replacing the C6H4–CO–NH- a group with nitrogen-containing heterocyclic rings and replacement of D-Glu fraction with an aromatic ring containing –COOH,-OH, and other polar groups to enhance the binding affinity. These alterations resulted in improvement of glide score from −6.75 to −8.88 ​kcal/mol and increase in binding free energy from −61.36 to 83.71 ​kcal/mol (M. Azam et al., 2019).

Fig. 7.

Fig. 7

Chemical structures of compounds D1,D2, D3 & D4 synthesized by modification of 2-thioxothiazolidin-4-one ring.

5.7. Screening of a group of commercial compound libraries

In 2019, Azam et al. screened a group of commercial compound libraries containing about 1.6 million small molecules against modeled MurD enzyme from Staphaureus through HTS and in-vitro validation. Based on binding free energy calculations and interaction of various ligands with the residues present in the catalytic pocket, the top ten compounds marked from H1 to H10 and were shortlisted for further studies. Crucial forces supporting ligand binding were found to be van der Waals and coulomb energy while electrostatic solvation energies opposed binding of the ligand molecules (M. A. Azam and Jupudi, 2019).

The highest inhibitory activity was displayed by compound H5 EnamineT6806127 (https://enamine.net/) (Fig. 8) with an IC50and MIC value of 7 ​μM and 128 ​μg/ml respectively showing the repressive effect on several commercial strains e.g., Staph. aureus NCIM 5021, Staph. aureus MRSA 43,300. No inhibitory effect was displayed by compound H10 (T0500-2187) against any of the tested strains which might be attributed to its poor permeability inside the bacterial cell. Ligand H5 (EnamineT6806127) interacted through forming a series of hydrogen bonds with the residues Lys19, Glu23, Gly80, and Gly147 and π-cation interaction with Lys19 residue to provide stability to the complex (M. A. Azam and Jupudi, 2019).

Fig. 8.

Fig. 8

Chemical structure of compound H5 (EnamineT6806127).

Some of the established MurD inhibitors were docked against E. coli MurD binding site and molecular simulation studies were carried out. Docking results revealed a common mode of interaction which exhibited by most of the inhibitors during recent studies. Major residues involved in the interaction between enzyme and inhibitor were Thr36, Arg37, His183, Lys319, Lys348, Thr321, Ser415, and Phe422. Non-polar interactions like Vander walls force was found to play a significant role in binding-stability of the inhibitor-protein complex while electrostatic interaction presented a minor role (M. A. Azam and Jupudi, 2017).

A total of 10,344 compounds from the Zinc (https://zinc.docking.org/) and PubChem database were screened against modeled MurD enzyme of Mycobacterium tuberculosis H37Rv based on molecular docking, Lipinski rule, and pharmacokinetic studies. The top four compounds ZINC11881196, ZINC12247644, ZINC14995379, and PubChem6185 were subjected to molecular simulation and MM-GBSA (molecular mechanics energies combined with generalized Born and surface area continuum solvation) and showed better values of binding free energies than the ATP. This study presented the above mentioned compounds as potential inhibitors of MurD which can be further endorsed for use as therapeutic drug (Isa, 2019).

5.8. Aza-stilbene derivatives

A library of synthesized ATP-competitive kinase inhibitors were screened against Mur ligases (Mur C, D, E & F) from E. coli. Four new scaffolds were identified that displayed a probability for the development of new drugs. Aza-stilbene derivative marked as 1 (Fig. 9A) was found as a potential inhibitor of the MurD enzyme (Hrast et al., 2019). NMR studies indicated that the binding of this inhibitor to the D-glutamic acid binding site is present in the C-terminal domain of the MurD. The compound acted in a competitive inhibition manner for D-Glutamic acid and disturbed the signals of the Leu416 methyl groups and was independent of the closing of the enzyme aided by ATP.

Fig. 9.

Fig. 9

9A. Chemical structure of ATP-dependent kinase inhibitors (aza-stilbene derivative); 9B. Chemical structures of compounds ZINC19221101 & ZINC12454357.

IC50value of compound 1 against MurD enzyme was found to be 104 ​μM. No inhibitory effect was displayed by compound 1 against any of the tested gram-negative or gram-positive organisms (E.coli & Staph aureus). The reason for this might be attributed to their low penetration effect which suggested further structural modifications need to be done to the parent compound to increase the inhibitory potency against various groups of Mur ligases (Hrast et al., 2019).

5.9. Molecular docking and simulation studies on compounds contained in zinc database

Molecular docking and simulation studies were done on about 6,42,759 compounds from the Zinc database (https://zinc.docking.org/) against the MurD enzyme from Acinetobacter baumannii prepared from E. coli (PDB ID: 4UAG) by homology modeling (Jha et al., 2020). Two compounds - ZINC19221101 and ZINC12454357 (Fig. 9 B)with binding free energy values of −62.6 ​± ​5.6 ​kcal/mol and −46.1 ​± ​2.6 ​kcal/mol respectively were the most promising candidates discovered for further validation. MD simulation studies showed compound ZINC19221101 to interact via hydrogen bonds with Ala122, Lys123, Ser124, and Asn146 residues. At the same time, it showed π-interactions with Lys123, Glu165, Lys330, Phe434, and Tyr440 residues and Vander wall interactions with residues Arg313, Thr332, and Lys364 (Jha et al., 2020).

Compound ZINC12454357 interacted with the residue Lys123, Asn146 (conserved residue), Lys364, and Tyr440 of MurD enzyme through hydrogen bonds. π-interactions were formed with the residues Glu165, Phe169, His191 (conserved residue), and Lys330 while Vander Walls interactions were formed with residue Pro80, Gly81 (catalytically conserved residue), Ser120, Asn121, Ala122, Leu147, Gly148, Ser167, Phe434, Ser439, and Asn441(Jha et al., 2020).

5.10. Phenoxyacetohydrazide derivatives

A set of phenoxyacetohydrazide derivatives (marked as 4a to 4k, Fig. 10, Table 5)were manufactured and characterized against Staph aureus MurD. Antibacterial activity analysis showed that compounds 4a, 4j, and 4k displayed an inhibitory effect on Staph aureusNCIM 5022 having MIC of 64 ​μg/ml. These compounds also revealed an inhibitory effect on MRSA strain ATCC 43300 with MIC of 128 ​μg/ml. Amongst all the examined compounds 4c and 4j showed the most powerful activity, sequentially against B. subtilis strain NCIM 2545 and Klebsiella pneumoniae strain NCIM 2706. Compound 4d expressed activity on Pseudomonas aeruginosa strain NCIM 2036 with MIC value of 64 ​μg/ml. Enzyme assay revealed that compound 4k exhibited the greatest inhibitory effect on Staph aureus MurD with an IC50 value of 35.80 ​μM. Sulfonylhydrazides derivatives were found to be more effective than hydrazides which might be due to the presence of SO2 group (Jupudi et al., 2021).

Fig. 10.

Fig. 10

Chemical structure of Parent phenoxyacetohydrazide structure.

Table 5.

Substituent groups attached to parent Phenoxyacetohydrazide structure in compounds from 4a-4k.

Cpd. marked R1 Gp. R2 Gp. X Gp. Ar Gp.
4a -Cl -H >carbonyl -2-furyl
4b -H -OCH3 >carbonyl -2-furyl
4c -Cl -Cl >carbonyl -2-Cl-C6H4
4d -Cl -Cl >carbonyl −3,5-diNO2-C6H3
4e -Cl -Cl >carbonyl -3-Br-C6H4
4f -Cl -Cl >carbonyl -4-Cl-C6H4
4g -H -NO2 >carbonyl −2,4-di–CH3O–C6H3
4h -H -NO2 >carbonyl −2,4-di-Cl-C6H3
4i -H -OCH3 >carbonyl -2-CH3-C6H4
4j -Cl -H >SO2 -C6H4
4k -H -OCH3 >SO2 -4-Cl-3-COOH-C6H3

Molecular docking and binding free energy calculations on MurD from Staph aureus via homology modeling showed that the vander Walls interaction is to be the major contributor for inhibitor-protein binding stability rather than electrostatic interactions (Jupudi et al., 2021).

5.11. Aza-Stilebin analogues

A set of 20 synthetic aza-stilbene derivatives were evaluated against Mur ligases C, D, E & F from Staph aureus. Weak antibacterial activities towards E. coli and Staph aureuswere seen by most of these derivatives. Two compounds marked as 30 and 31 (Fig. 11) showed moderate activities towards Staph aureus exhibiting MIC values of 0.125 and 0.031 ​mM, respectively.

Fig. 11.

Fig. 11

Chemical structures of Aza-stilbene derivatives marked as compound 30 and 31.

Molecular docking studies showed that the tetrazole ring interacts with the enzyme with a higher number of hydrogen bonds while pyridine, phenyl, and furan fractions forms weak interaction with the enzyme. These study suggested that possible structural modifications are needed to increase the binding affinity and inhibitory effect (Hrast et al., 2021).

5.12. Screening of CHEMBEL database against mycobacterial mur enzymes

CHEMBL database (https://www.ebi.ac.uk/chembl/) was screened by molecular docking and simulation studies against homology modeled Mur enzymes (Mur A, B, C, D, E & F) of Mycobacterium tuberculosis (Mtb). CHEMBL446262 (Fig. 12) was found out to be the best-docked compound against all the modeled Mur enzymes of Mtb. The compound was found to form active Hydrogen -bond interactions with Ser129, Arg141,Leu144, Ile148, Ser150, Glu166, Asp194, Arg446, and Met448 residues of the enzyme. Suggested further experimental validation for the development of new inhibitors (Kumari and Subbarao, 2021).

Fig. 12.

Fig. 12

Chemical structure of compound CHEMBL426262.

6. Conclusion and future prospect

The MurD is an ATP- dependent cytoplasmic cell wall biosynthesis enzyme that is gaining interest due to its important role in bacterial growth and its absence in humans. Structural studies on MurD has revealed details about its substrate binding pattern and catalysis mechanism (Bertrand et al., 1997, 1999; Bertrand et al., 1999; Humljan et al., 2006; Tomašić et al., 2010). The MurD along with other Mur ligases (Mur C, E & F) have a common mechanism of action and a conserved ATP binding site having similar sequences (El Zoeiby et al., 2003). Despite the many promising effects of MurD inhibitors identified so far, they have not been exploited significantly for antibacterial activity studies. This is presumably due to the failure of inhibitors to traverse the cytoplasmic barrier of the bacteria. Therefore, attempts need to be made to devise novel inhibitors or make structural and chemical modifications in the existing inhibitors to subdue cell membrane barrier obstacles. Further, as the MurD enzyme undergoes several conformational changes in its domain structure during its catalytic reaction (Perdih et al., 2014), some challenges need to be addressed while devising new inhibitors against such flexible moving target.

In silico or structure-based drug designing may be used to develop new inhibitors that can restrain the action of MurD enzyme. Currently, in-silico techniques have been used successfully in the development of drugs for different diseases like HIV/AIDS (amprenavir) and influenza (zanamivir) (jSimmons et al., 2010). In the recent past, there has been a gradual increase in the use of various computer-aided drug design methods (Turk et al., 2009)like molecular docking to design novel inhibitors against various biological targets like Type 1 TGF beta - receptor kinase inhibitor&aurora kinase A inhibitor (Sethi et al., 2019) including the MurD enzyme. Earlier, most of the drug discovery processes included conventional methods that comprised of tedious and repetitive experimental techniques and identification of ligands for the targets (protein/enzyme)by utilizing various chemical and proteomics strategies. These are usually extensive, expensive, and time-consuming. Nevertheless, the advancements in bioinformatics synchronously with progress in computer application tools and means have transformed the drug designing process against novel targets. Hence, there is a need for the effective use of various in-silico methods in combination with experimental work to design effective inhibitors against MurD enzyme. At the same time, various challenges like cell membrane permeability barrier and conformational changes need to be effectively managed which needs more experimental research data in the current field. So, in order to counter increasing resistance among bacterial pathogens toward the existing antibiotics, there is a growing need for the persistent development of clinically important novel antibiotics with entirely novel modes of action (Bratkovič et al., 2008; Zidar et al., 2010).

Funding

The work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

Vinita Gaur: Conceptualization, Writing – original draft, Data curation. Surojit Bera: Conceptualization, Writing – original draft, Data curation, Writing – review & editing, Supervision.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The author wishes to thank Lovely professional University for their help and necessary support for carrying out the present work.

Data availability

No data was used for the research described in the article.

References

  1. Amineni U., Pradhan D., Marisetty H. In silico identification of common putative drug targets in Leptospira interrogans. Journal of chemical biology. 2010;3(4):165–173. doi: 10.1007/s12154-010-0039-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azam M., Jupudi S., Saha N., Paul R. Combining molecular docking and molecular dynamics studies for modelling Staphylococcus aureus MurD inhibitory activity. SAR QSAR Environ. Res. 2019;30(1):1–20. doi: 10.1080/1062936X.2018.1539034. [DOI] [PubMed] [Google Scholar]
  3. Azam M.A., Jupudi S. Extra precision docking, free energy calculation and molecular dynamics studies on glutamic acid derivatives as MurD inhibitors. Comput. Biol. Chem. 2017;69:55–63. doi: 10.1016/j.compbiolchem.2017.05.004. [DOI] [PubMed] [Google Scholar]
  4. Azam M.A., Jupudi S. Structure-based virtual screening to identify inhibitors against Staphylococcus aureus MurD enzyme. Struct. Chem. 2019;30(6):2123–2133. [Google Scholar]
  5. Azam M.A., Jupudi S. MurD inhibitors as antibacterial agents: a review. Chem. Pap. 2020;74(6):1697–1708. doi: 10.1007/s11224-019-01330-z. [DOI] [Google Scholar]
  6. Barreteau H., Kovač A., Boniface A., Sova M., Gobec S., Blanot D. Cytoplasmic steps of peptidoglycan biosynthesis. FEMS Microbiol. Rev. 2008;32(2):168–207. doi: 10.1111/j.1574-6976.2008.00104.x. [DOI] [PubMed] [Google Scholar]
  7. Barreteau H., Sosič I., Turk S., Humljan J., Tomašić T., Zidar N.…Kikelj D. MurD enzymes from different bacteria: evaluation of inhibitors. Biochem. Pharmacol. 2012;84(5):625–632. doi: 10.1016/j.bcp.2012.06.006. [DOI] [PubMed] [Google Scholar]
  8. Bertrand J.A., Auger G., Fanchon E., Martin L., Blanot D., Van Heijenoort J., Dideberg O. Crystal structure of UDP-N-acetylmuramoyl-L-alanine: D-glutamate ligase from Escherichia coli. EMBO J. 1997;16(12):3416–3425. doi: 10.1093/emboj/16.12.3416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bertrand J.A., Auger G., Martin L., Fanchon E., Blanot D., Le Beller D.…Dideberg O. Determination of the MurD mechanism through crystallographic analysis of enzyme complexes. J. Mol. Biol. 1999;289(3):579–590. doi: 10.1006/jmbi.1999.2800. [DOI] [PubMed] [Google Scholar]
  10. Bertrand J.A., Fanchon E., Martin L., Chantalat L., Auger G., Blanot D.…Dideberg O. Open” structures of MurD: domain movements and structural similarities with folylpolyglutamate synthetase. J. Mol. Biol. 2000;301(5):1257–1266. doi: 10.1006/jmbi.2000.3994. [DOI] [PubMed] [Google Scholar]
  11. Bouhss A., Dementin S., Parquet C., Mengin-Lecreulx D., Bertrand J.A., Le Beller D., et al. Role of the ortholog and paralog amino acid invariants in the active site of the UDP-MurNAc-L-alanine: D-glutamate ligase (MurD) Biochemistry. 1999;38(38):12240–12247. doi: 10.1021/bi.990517r. [DOI] [PubMed] [Google Scholar]
  12. Bratkovič T., Lunder M., Urleb U., Štrukelj B. Peptide inhibitors of MurD and MurE, essential enzymes of bacterial cell wall biosynthesis. J. Basic Microbiol. 2008;48(3):202–206. doi: 10.1002/jobm.200700133. [DOI] [PubMed] [Google Scholar]
  13. Bugg T.D., Braddick D., Dowson C.G., Roper D.I. Bacterial cell wall assembly: still an attractive antibacterial target. Trends Biotechnol. 2011;29(4):167–173. doi: 10.1016/j.tibtech.2010.12.006. [DOI] [PubMed] [Google Scholar]
  14. Daniel R.A., Errington J. DNA sequence of themurE-murD region of Bacillus subtilis 168. Microbiology. 1993;139(2):361–370. doi: 10.1099/00221287-139-2-361. [DOI] [PubMed] [Google Scholar]
  15. El-Sherbeini M., Geissler W.M., Pittman J., Yuan X., Wong K.K., Pompliano D.L. Cloning and expression of Staphylococcus aureus and Streptococcus pyogenes murD genes encoding uridine diphosphate N-acetylmuramoyl-L-alanine: D-glutamate ligases. Gene. 1998;210(1):117–125. doi: 10.1099/00221287-139-2-361. [DOI] [PubMed] [Google Scholar]
  16. El Zoeiby A., Sanschagrin F., Levesque R.C. Structure and function of the Mur enzymes: development of novel inhibitors. Mol. Microbiol. 2003;47(1):1–12. doi: 10.1046/j.1365-2958.2003.03289.x. [DOI] [PubMed] [Google Scholar]
  17. Favini-Stabile S., Contreras-Martel C., Thielens N., Dessen A. M re B and M ur G as scaffolds for the cytoplasmic steps of peptidoglycan biosynthesis. Environ. Microbiol. 2013;15(12):3218–3228. doi: 10.1111/1462-2920.12171. [DOI] [PubMed] [Google Scholar]
  18. Feng Ruoyin . Hokkaido University; 2019. Studies on New Enzymes Responsible for Peptidoglycan Biosynthesis." PhD Diss. [DOI] [Google Scholar]
  19. Hara H., Yasuda S., Horiuchi K., Park J.T. A promoter for the first nine genes of the Escherichia coli mra cluster of cell division and cell envelope biosynthesis genes, including ftsI and ftsW. J. Bacteriol. 1997;179(18):5802–5811. doi: 10.1128/jb.179.18.5802-5811.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hrast M., Knez D., Zdovc I., Barreteau H., Gobec S. Mur ligases inhibitors with azastilbene scaffold: expanding the structure–activity relationship. Bioorg. Med. Chem. Lett. 2021;40 doi: 10.1016/j.bmcl.2021.127966. [DOI] [PubMed] [Google Scholar]
  21. Hrast M., Rožman K., Ogris I., Škedelj V., Patin D., Sova M.…Zega A. Evaluation of the published kinase inhibitor set to identify multiple inhibitors of bacterial ATP-dependent mur ligases. J. Enzym. Inhib. Med. Chem. 2019;34(1):1010–1017. doi: 10.1080/14756366.2019.1608981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hrast M., Sosič I., Šink R., Gobec S. Inhibitors of the peptidoglycan biosynthesis enzymes MurA-F. Bioorg. Chem. 2014;55:2–15. doi: 10.1016/j.bioorg.2014.03.008. [DOI] [PubMed] [Google Scholar]
  23. Humljan J., Kotnik M., Boniface A., Šolmajer T., Urleb U., Blanot D., Gobec S. A new approach towards peptidosulfonamides: synthesis of potential inhibitors of bacterial peptidoglycan biosynthesis enzymes MurD and MurE. Tetrahedron. 2006;62(47):10980–10988. doi: 10.1016/j.tet.2006.08.030. [DOI] [Google Scholar]
  24. Humljan J., Kotnik M., Contreras-Martel C., Blanot D., Urleb U., Dessen A.…Gobec S. Novel naphthalene-N-sulfonyl-D-glutamic acid derivatives as inhibitors of MurD, a key peptidoglycan biosynthesis enzyme. J. Med. Chem. 2008;51(23):7486–7494. doi: 10.1021/jm800762u. [DOI] [PubMed] [Google Scholar]
  25. Ikeda M., Wachi M., Ishino F., Matsuhashi M. Nucleotide sequence involving murD and an open reading frame ORF-Y spacing murF and ftsW in Escherichia coli. Nucleic Acids Res. 1990;18(4):1058. doi: 10.1093/nar/18.4.1058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ikeda M., Wachi M., Jung H.K., Ishino F., Matsuhashi M. Homology among MurC, MurD, MurE and MurF proteins in Escherichia coli and that between E. coli MurG and a possible MurG protein in Bacillus subtilis. J. Gen. Appl. Microbiol. 1990;36(3):179–187. doi: 10.2323/jgam.36.179. [DOI] [Google Scholar]
  27. Isa M.A. Homology modeling and molecular dynamic simulation of UDP-N-acetylmuramoyl-l-alanine-d-glutamate ligase (MurD) from Mycobacterium tuberculosis H37Rv using in silico approach. Comput. Biol. Chem. 2019;78:116–126. doi: 10.1016/j.compbiolchem.2018.11.002. [DOI] [PubMed] [Google Scholar]
  28. Jha R.K., Khan R.J., Amera G.M., Singh E., Pathak A., Jain M.…Singh A.K. Identification of promising molecules against MurD ligase from Acinetobacter baumannii: insights from comparative protein modelling, virtual screening, molecular dynamics simulations and MM/PBSA analysis. J. Mol. Model. 2020;26(11):1–17. doi: 10.1007/s00894-020-04557-4. [DOI] [PubMed] [Google Scholar]
  29. Jupudi S., Azam M.A., Wadhwani A. Design, synthesis and molecular modelling of phenoxyacetohydrazide derivatives as Staphylococcus aureus MurD inhibitors. Chem. Pap. 2021;75(3):1221–1235. doi: 10.1007/s11696-020-01380-2. [DOI] [Google Scholar]
  30. Klugman K.P., Black S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc. Natl. Acad. Sci. USA. 2018;115(51):12896–12901. doi: 10.1073/pnas.1721095115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kotnik M., Humljan J., Contreras-Martel C., Oblak M., Kristan K., Hervé M.…Dessen A. Structural and functional characterization of enantiomeric glutamic acid derivatives as potential transition state analogue inhibitors of MurD ligase. J. Mol. Biol. 2007;370(1):107–115. doi: 10.1016/j.jmb.2007.04.048. [DOI] [PubMed] [Google Scholar]
  32. Kumari M., Subbarao N. Identification of novel multitarget antitubercular inhibitors against mycobacterial peptidoglycan biosynthetic Mur enzymes by structure-based virtual screening. J. Biomol. Struct. Dyn. 2021:1–12. doi: 10.1080/07391102.2021.1908913. [DOI] [PubMed] [Google Scholar]
  33. Li B., Webster T.J. Bacteria antibiotic resistance: new challenges and opportunities for implant-associated orthopedic infections. J. Orthop. Res. 2018;36(1):22–32. doi: 10.1002/jor.23656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lin X., Li X., Lin X. A review on applications of computational methods in drug screening and design. Molecules. 2020;25(6):1375. doi: 10.3390/molecules25061375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Liu Y., Ding S., Shen J., Zhu K. Nonribosomal antibacterial peptides that target multidrug-resistant bacteria. Nat. Prod. Rep. 2019;36(4):573–592. doi: 10.1039/C8NP00031J. [DOI] [PubMed] [Google Scholar]
  36. Liu F., Meng H., Sun Z., Li D., Jin Y., Yang Z.…Chen J. Advances in the research of inhibitors of enzymes of bacterial peptidoglycan biosynthesis. Yao xue xue bao= Acta pharmaceutica Sinica. 2017;52(3):362–370. PMID: 29979555. [PubMed] [Google Scholar]
  37. Mengin-Lecreulx D., Parquet C., Desviat L.R., Plá J., Flouret B., Ayala J.A., van Heijenoort J. Organization of the murE-murG region of Escherichia coli: identification of the murD gene encoding the D-glutamic-acid-adding enzyme. J. Bacteriol. 1989;171(11):6126–6134. doi: 10.1128/jb.171.11.6126-6134.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Miyachiro M.M., Granato D., Trindade D.M., Ebel C., Paes Leme A.F., Dessen A. Complex formation between Mur enzymes from Streptococcus pneumoniae. Biochemistry. 2019;58(30):3314–3324. doi: 10.1128/jb.171.11.6126-6134.1989. [DOI] [PubMed] [Google Scholar]
  39. Naha A., Miryala S.K., Debroy R., Ramaiah S., Anbarasu A. Elucidating the multi-drug resistance mechanism of Enterococcus faecalis V583: a gene interaction network analysis. Gene. 2020;748 doi: 10.1016/j.gene.2020.144704. [DOI] [PubMed] [Google Scholar]
  40. Nakagawa H., Saio T., Nagao M., Inoue R., Sugiyama M., Ajito S.…Kawakita Y. Conformational dynamics of a multidomain protein by neutron scattering and computational analysis. Biophys. J. 2021 doi: 10.1016/j.bpj.2021.07.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Ogasawara Y., Dairi T. Discovery of an alternative pathway of peptidoglycan biosynthesis: a new target for pathway specific inhibitors. J. Ind. Microbiol. Biotechnol. 2021;48(9–10) doi: 10.1093/jimb/kuab038. kuab038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Perdih A., Hrast M., Barreteau H.l. n., Gobec S., Wolber G., Solmajer T. Inhibitor design strategy based on an enzyme structural flexibility: a case of bacterial MurD ligase. J. Chem. Inf. Model. 2014;54(5):1451–1466. doi: 10.1021/ci500104m. [DOI] [PubMed] [Google Scholar]
  43. Pratviel-Sosa F., Mengin-Lecreulx D., Van Heijenoort J. Over-production, purification and properties of the uridine diphosphate N-acetylmuramoyl-l-alanine: d-glutamate ligase from Escherichia coli. Eur. J. Biochem. 1991;202(3):1169–1176. doi: 10.1111/j.1432-1033.1991.tb16486.x. [DOI] [PubMed] [Google Scholar]
  44. Saio T., Ogura K., Kumeta H., Kobashigawa Y., Shimizu K., Yokochi M.…Inagaki F. Ligand-driven conformational changes of MurD visualized by paramagnetic NMR. Sci. Rep. 2015;5(1):1–11. doi: 10.1038/srep16685. 2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sethi A., Joshi K., Sasikala K., Alvala M. Molecular docking in modern drug discovery: principles and recent applications. Drug Discovery and Development-New Advances. 2019:1–21. doi: 10.5772/intechopen.77685. [DOI] [Google Scholar]
  46. Shinde Y., Ahmad I., Surana S., Patel H. The mur enzymes chink in the armour of Mycobacterium tuberculosis cell wall. Eur. J. Med. Chem. 2021;222 doi: 10.1016/j.ejmech.2021.113568. [DOI] [PubMed] [Google Scholar]
  47. Sibinelli-Sousa S., Hespanhol J.T., Bayer-Santos E. Targeting the Achilles' heel of bacteria: different mechanisms to break down the peptidoglycan cell wall during bacterial warfare. J. Bacteriol. 2021;203(7) doi: 10.1128/JB.00478-20. e00478-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Simčič M., Pureber K., Kristan K., Urleb U., Kocjan D., Grdadolnik S.G. A novel 2-oxoindolinylidene inhibitor of bacterial MurD ligase: enzyme kinetics, protein-inhibitor binding by NMR and a molecular dynamics study. Eur. J. Med. Chem. 2014;83:92–101. doi: 10.1016/j.ejmech.2014.06.021. [DOI] [PubMed] [Google Scholar]
  49. Simčič M., Sosič I., Hodošček M., Barreteau H., Blanot D., Gobec S., Grdadolnik S.G. The binding mode of second-generation sulfonamide inhibitors of MurD: clues for rational design of potent MurD inhibitors. PLoS One. 2012;7(12) doi: 10.1371/journal.pone.0052817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Simmons K.J., Chopra I., Fishwick C.W. Structure-based discovery of antibacterial drugs. Nat. Rev. Microbiol. 2010;8(7):501–510. doi: 10.1038/nrmicro2349. [DOI] [PubMed] [Google Scholar]
  51. Šink R., Barreteau H., Patin D., Mengin-Lecreulx D., Gobec S., Blanot D. MurD enzymes: some recent developments. Biomol. Concepts. 2013;4(6):539–556. doi: 10.1515/bmc-2013-0024. [DOI] [PubMed] [Google Scholar]
  52. Šink R., Kotnik M., Zega A., Barreteau H., Gobec S., Blanot D.…Contreras-Martel C. Crystallographic study of peptidoglycan biosynthesis enzyme MurD: domain movement revisited. PLoS One. 2016;11(3) doi: 10.1371/journal.pone.0152075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Sosič I., Barreteau H., Simčič M., Šink R., Cesar J., Zega A.…Amoroso A. Second-generation sulfonamide inhibitors of D-glutamic acid-adding enzyme: activity optimisation with conformationally rigid analogues of D-glutamic acid. Eur. J. Med. Chem. 2011;46(7):2880–2894. doi: 10.1016/j.ejmech.2011.04.011. [DOI] [PubMed] [Google Scholar]
  54. Stein A.J., Sather A., Shakelford G., Joachimiak A. 2009. The Crystal Structure of UDP-N-Acetylmuramoylalanine-D-Glutamate (MurD) Ligase from Streptococcus Agalactiae to 1.5A. ;yet to be published. [Google Scholar]
  55. Takahashi M., Yamaguchi E., Uchida T. Thermophilic DNA ligase. Purification and properties of the enzyme from Thermus thermophilus HB8. J. Biol. Chem. 1984;259(16):10041–10047. doi: 10.1016/S0021-9258(18)90924-5. [DOI] [PubMed] [Google Scholar]
  56. Talevi A. Computer-aided drug design: an overview. Computational drug discovery and design. 2018:1–19. doi: 10.1007/978-1-4939-7756-7_1. [DOI] [PubMed] [Google Scholar]
  57. Thakur M., Chakraborti P.K. Ability of PknA, a mycobacterial eukaryotic-type serine/threonine kinase, to transphosphorylate MurD, a ligase involved in the process of peptidoglycan biosynthesis. Biochem. J. 2008;415(1):27–33. doi: 10.1042/BJ20080234. [DOI] [PubMed] [Google Scholar]
  58. Tomašić T., Šink R., Zidar N., Fic A., Contreras-Martel C., Dessen A.…Gobec S. Dual inhibitor of MurD and MurE ligases from Escherichia coli and Staphylococcus aureus. ACS Med. Chem. Lett. 2012;3(8):626–630. doi: 10.1021/ml300047h. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Tomašić T., Zidar N., Kovač A., Turk S., Simčič M., Blanot D.…Zega A. 5-Benzylidenethiazolidin-4-ones as multitarget inhibitors of bacterial Mur ligases. ChemMedChem: Chemistry Enabling Drug Discovery. 2010;5(2):286–295. doi: 10.1002/cmdc.200900449. [DOI] [PubMed] [Google Scholar]
  60. Tomašić T., Zidar N., Sink R., Kovač A., Blanot D., Contreras-Martel C.…Gobec S. Structure-based design of a new series of D-glutamic acid based inhibitors of bacterial UDP-N-acetylmuramoyl-L-alanine: D-glutamate ligase (MurD) J. Med. Chem. 2011;54(13):4600–4610. doi: 10.1021/jm2002525. [DOI] [PubMed] [Google Scholar]
  61. Turk S., Kovač A., Boniface A., Bostock J.M., Chopra I., Blanot D., Gobec S. Discovery of new inhibitors of the bacterial peptidoglycan biosynthesis enzymes MurD and MurF by structure-based virtual screening. Bioorg. Med. Chem. 2009;17(5):1884–1889. doi: 10.1016/j.bmc.2009.01.052. [DOI] [PubMed] [Google Scholar]
  62. Vollmer W., Blanot D., de Pedro M.A. Peptidoglycan structure and architecture. FEMS Microbiol. Rev. 2008;32:149–167. doi: 10.1111/j.1574-6976.2007.00094.x. pmid:18194336. [DOI] [PubMed] [Google Scholar]
  63. Walsh A.W., Falk P.J., Thanassi J., Discotto L., Pucci M.J., Ho H.-T. Comparison of the D-glutamate-adding enzymes from selected gram-positive and gram-negative bacteria. J. Bacteriol. 1999;181(17):5395–5401. doi: 10.1128/JB.181.17.5395-5401.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Watanabe H., Mori H., Itoh T., Gojobori T. Genome plasticity as a paradigm of eubacteria evolution. J. Mol. Evol. 1997;44(1):S57–S64. doi: 10.1007/PL00000052. [DOI] [PubMed] [Google Scholar]
  65. Wedler F.C., Ley B.W. Homoserine dehydrogenase-I (Escherichia coli): action of monovalent ions on catalysis and substrate association-dissociation. Arch. Biochem. Biophys. 1993;301(2):416–423. doi: 10.1006/abbi.1993.1165. [DOI] [PubMed] [Google Scholar]
  66. Zdouc M., Schink J., Lešnik S., Rožman K., Konc J., Janežič D., Gobec S. Docking study with biological validation on bacterial enzyme MurD. Chemical Data Collections. 2018;13:139–155. doi: 10.1016/j.cdc.2018.02.003. [DOI] [Google Scholar]
  67. Zheng X., Zheng T., Liao Y., Luo L. Identification of potential inhibitors of MurD enzyme of Staphylococcus aureus from a marine natural product library. Molecules. 2021;26(21):6426. doi: 10.3390/molecules26216426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Zidar N., TomašiĆ T., Šink R., Kovač A., Patin D., Blanot D.…Zega A. New 5-benzylidenethiazolidin-4-one inhibitors of bacterial MurD ligase: design, synthesis, crystal structures, and biological evaluation. Eur. J. Med. Chem. 2011;46(11):5512–5523. doi: 10.1016/j.ejmech.2011.09.017. [DOI] [PubMed] [Google Scholar]
  69. Zidar N., Tomašić T., Sink R., Rupnik V., Kovac A., Turk S.…Dessen A. Discovery of novel 5-benzylidenerhodanine and 5-benzylidenethiazolidine-2, 4-dione inhibitors of MurD ligase. J. Med. Chem. 2010;53(18):6584–6594. doi: 10.1021/jm100285g. [DOI] [PubMed] [Google Scholar]

Web References:

  1. publications https://www.who.int/publications/m/item/comprehensive-review-of-the-who-global-action-plan-on-antimicrobial-resistance---management-response---march-2022
  2. rcsb https://www.rcsb.org/
  3. ebi https://www.ebi.ac.uk/Tools/msa/clustalo/
  4. uniprot https://www.uniprot.org/

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

No data was used for the research described in the article.


Articles from Current Research in Pharmacology and Drug Discovery are provided here courtesy of Elsevier

RESOURCES